SCHEMBL6256563

SCHEMBL6256563

O=C1CCNc2cc(Cl)ccc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
ALDH1A1 P00352 2/20 0.54
HPGD P15428 2/20 0.54
LMNA P02545 1/20 0.54
TP53 P04637 1/20 0.54
POLB P06746 1/20 0.54
GAA P10253 1/20 0.54
ALOX15 P16050 1/20 0.54
ALOX12 P18054 1/20 0.54
CASP1 P29466 1/20 0.54
MPI P34949 1/20 0.54
HTT P42858 1/20 0.54
CASP7 P55210 1/20 0.54
HSD17B10 Q99714 1/20 0.54
PARP10 Q53GL7 2/20 0.50
F7 P08709 1/20 0.50
PARP1 P09874 1/20 0.50
F3 P13726 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30051842 0.89 GAA (0.44) MEN1KMT2AALDH1A1HPGDLMNA
SCHEMBL3531650 0.89 GAA (0.44) MEN1KMT2AALDH1A1HPGDLMNA
SCHEMBL6977492 0.85 MEN1 (0.58) MEN1KMT2AALDH1A1HPGDLMNA
SCHEMBL31239363 0.81 CES1 (0.48) MEN1KMT2AGAAPARP10F7
SCHEMBL17750046 0.80 PARP10 (0.67) MEN1KMT2AALDH1A1HPGDLMNA
SCHEMBL4000581 0.78 MEN1 (0.54) MEN1KMT2AALDH1A1HPGDLMNA
SCHEMBL3105252 0.78 MEN1 (0.54) MEN1KMT2AALDH1A1HPGDLMNA
SCHEMBL6171659 0.78 MEN1 (0.54) MEN1KMT2AALDH1A1HPGDLMNA
SCHEMBL30274589 0.78 MEN1 (0.54) MEN1KMT2AALDH1A1HPGDLMNA
SCHEMBL10989615 0.78 ALDH1A1 (0.54) MEN1KMT2AALDH1A1HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4585867-A Process for the preparation of 4-quinolinones RHONE-POULENC SANTE (FR) 1986-04-29 US claimed
EP-0056765-B1 PREPARATION OF 4-HYDROXYQUINOLINES RHONE-POULENC SANTE (FR) 1985-06-19 EP claimed
EP-0056763-B1 PROCESS FOR THE PREPARATION OF 4-QUINOLINONES RHONE-POULENC SANTE (FR) 1984-07-04 EP claimed
EP-0056766-B1 PROCESS FOR THE PREPARATION OF 4-AMINO-CHLOROQUINOLINES RHONE-POULENC SANTE (FR) 1984-05-16 EP claimed
EP-0056764-B1 PROCESS FOR THE PREPARATION OF 7-CHLORO-1,2,3,4-TETRAHYDRO-4-QUINOLONE RHONE-POULENC SANTE (FR) 1983-12-28 EP claimed
US-4421920-A AMINATION, AROMATIZATION, RUTHENIUM CATALYST RHONE-POULENC SANTE (FR) 1983-12-20 US claimed
US-4421918-A Process for the preparation of 7-chloro-1,2,3,4-tetrahydroquinolin-4-one RHONE-POULENC SANTE (FR) 1983-12-20 US claimed
US-4412076-A Preparation of 4-hydroxyquinolines RHONE-POULENC SANTE (FR) 1983-10-25 US claimed
US-4412075-A Process for the preparation of quinolin-4-ones RHONE-POULENC SANTE (FR) 1983-10-25 US claimed
JP-57171971-A None JP disclosed
EP-3287441-B1 ACYLATED 4-AMINOPIPERIDINES AS INHIBITORS OF SERINE PALMITOYLTRANSFERASE TAKEDA PHARMACEUTICALS CO (JP) 2021-06-09 EP disclosed
CN-107848971-B Heterocyclic compounds 武田药品工业株式会社 2021-03-26 CN disclosed
US-10189785-B2 Heterocyclic compound TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) 2019-01-29 US disclosed
US-20180170874-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-06-21 US disclosed
US-4412076-A Preparation of 4-hydroxyquinolines RHONE-POULENC SANTE (FR) 1983-10-25 US disclosed
JP-S57171971-A MANUFACTURE OF 7-CHLORO-1,2,3,4- TETRAHYDROQUINOLINE-4-ONE RHONE POULENC SANTE 1982-10-22 JP disclosed
EP-0056764-A1 Process for the preparation of 7-chloro-1,2,3,4-tetrahydro-4-quinolone RHONE-POULENC SANTE (FR) 1982-07-28 EP disclosed
US-4273775-A PREVENTION OF OCULAR AND NEURITIC, DIABETIS-ASSOCIATED COMPLICATIONS PFIZER INC. (US) 1981-06-16 US disclosed
EP-0021704-A1 Spiro-hydantoin derivatives, process for their preparation and pharmaceutical compositions thereof PFIZER INC. (US) 1981-01-07 EP disclosed
US-4235911-A TETRAHYDROQUINOLINE-DERIVED SPIRO-HYDANTOINS, CONTROL OF DIABETIC COMPLICATIONS PFIZER INC. (US) 1980-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10189785-B2 Heterocyclic compound SPTLC1, SPTLC2, NPC1 MEN1 1270/4885KMT2A 1530/4885ALDH1A1 2775/4885
US-20180170874-A1 HETEROCYCLIC COMPOUND SPTLC1, SPTLC2, NPC1 MEN1 1270/4885KMT2A 1530/4885ALDH1A1 2775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.